fasudil has been researched along with Obesity in 2 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| " Treatment with the Rho-kinase inhibitor fasudil attenuated weight gain and insulin resistance in mice on a HFD." | 3.77 | Rho and Rho-kinase activity in adipocytes contributes to a vicious cycle in obesity that may involve mechanical stretch. ( Fujimura, K; Hara, Y; Hasegawa, K; Hayashi, K; Homma, K; Hosoya, K; Itoh, H; Minakuchi, H; Nakayama, K; Saito, M; Tanabe, Y; Tatematsu, S; Tokuyama, H; Wakino, S; Washida, N; Yoshioka, K, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hara, Y | 1 |
| Wakino, S | 1 |
| Tanabe, Y | 1 |
| Saito, M | 1 |
| Tokuyama, H | 1 |
| Washida, N | 1 |
| Tatematsu, S | 1 |
| Yoshioka, K | 1 |
| Homma, K | 1 |
| Hasegawa, K | 1 |
| Minakuchi, H | 1 |
| Fujimura, K | 1 |
| Hosoya, K | 1 |
| Hayashi, K | 1 |
| Nakayama, K | 1 |
| Itoh, H | 1 |
| Schinzari, F | 1 |
| Tesauro, M | 1 |
| Rovella, V | 1 |
| Di Daniele, N | 1 |
| Gentileschi, P | 1 |
| Mores, N | 1 |
| Campia, U | 1 |
| Cardillo, C | 1 |
2 other studies available for fasudil and Obesity
| Article | Year |
|---|---|
Rho and Rho-kinase activity in adipocytes contributes to a vicious cycle in obesity that may involve mechanical stretch.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adipocytes; Animals; Diet, Fat-Restricted; Insulin Re | 2011 |
Rho-kinase inhibition improves vasodilator responsiveness during hyperinsulinemia in the metabolic syndrome.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Antioxidants; Drug Resistance; Endothelium, Va | 2012 |